Accuray Inc has entered into a $55 million agreement to issue Series A Preferred Stock, which includes an immediate cash investment of $15 million and the conversion of $40 million in existing debt. This strategic financing aims to stabilize the company's financial position as shares drop significantly year-to-date.

Key Highlights

  • Accuray Inc secures $55,000,000 through Series A Preferred Stock financing.
  • Series A Preferred Stock priced at $1,000 per share with an 8% annual dividend.
  • Preferred shares convertible into common shares at a ratio of 2,000 per $1,000 principal.

Accuray Inc (NASDAQ: ARAY) has finalized a financing arrangement that provides a combined $55,000,000 of capital through the issuance of Series A Preferred Stock.

Deal Structure

Under the agreement, each share of Series A Preferred Stock is priced at $1,000. The preferred shares will pay an annual dividend at an 8% rate and may be converted into common shares at a ratio of 2,000 common shares for each $1,000 of preferred principal, which translates to an initial conversion price of roughly $0.50 per share. In addition, the company will cancel outstanding warrants representing approximately 27.6 million shares, simplifying the capital structure.

Separate warrant packages remain exercisable for roughly 17.2 million shares at $1.68 per share, 6.1 million shares at $1.50 per share, and 4.3 million shares at $1.25 per share.

Context Within the Medical‑Technology Sector

Accuray operates in the medical‑technology arena, providing precision radiation solutions. The sector has experienced heightened capital‑intensity pressures as firms pursue advanced research and regulatory approvals. By securing this financing, Accuray aligns its capital resources with the broader industry trend of leveraging convertible preferred instruments to balance debt reduction and equity growth.

The inclusion of a reverse split of the Company’s common stock, with a par value of $0.001 per share, is intended to meet exchange listing requirements and improve market perception.

Governance and Next Steps

The agreement, filed with the Securities and Exchange Commission in Washington, D.C. Completion of the transaction will require approval from Accuray’s shareholders, after which the conversion of debt, issuance of preferred shares, and warrant adjustments will be executed. The company anticipates that the new capital will support ongoing development initiatives, enhance liquidity, and position Accuray for continued growth in a competitive healthcare market.

Outlook

With the financing now in place, Accuray is poised to advance its product pipeline while maintaining a capital structure that reflects both debt discipline and equity participation. Stakeholders will monitor the implementation of the preferred stock conversion, the associated warrant exercises, and any subsequent corporate actions, such as a reverse stock split that aims to establish a minimum common‑stock price of $8.00 per share. These steps are expected to reinforce the company’s financial footing and support its strategic objectives moving forward.

Analysis based on the Form 8-K filed 29 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.